Notably, FPA144 increased PD-L1-expressing cells in the tumor microenvironment, and the combination of FPA144 and RPM1-14, a PD-1 blockade, inhibited tumor growth by 49% (p < 0.001) (98). Here, CD274 is linked to neoplasm.